Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys

Osteoporosis International

Volumn 23, Issue 1, 2012, Pages 339-349

  Jerome, C ^a   Missbach, M ^b   Gamse, R ^b  

^a Think Bone Consulting Inc   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Anti resorptive; Cathepsin K; Macaca fascicularis; Osteoporosis; Primate

Indexed keywords

BALICATIB; CATHEPSIN K INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE TURNOVER; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; ENZYME INHIBITION; FEMALE; FEMUR; MACACA FASCICULARIS; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOPOROSIS; OVARIECTOMY; PERIOSTEUM; PRIMATE; PRIORITY JOURNAL; TREATMENT OUTCOME; VERTEBRA;

ANIMALS; BENZAMIDES; BODY WEIGHT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CATHEPSIN K; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; EATING; ESTRADIOL; FEMALE; FEMUR; HUMANS; LUMBAR VERTEBRAE; MACACA FASCICULARIS; ORGAN SIZE; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; PERIOSTEUM; PIPERAZINES; UTERUS;

EID: 84857370394     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1593-2     Document Type: Article

References (35)

1. Borges JL, Bilezikian JP (2006) Update on osteoporosis therapy. Arq Bras Endocrinol Metabol 50:755-763 (Pubitemid 44786011)
2. Girotra M, Rubin MR, Bilezikian JP (2006) Anabolic agents for osteoporosis: what is their likely place in therapy? Treat Endocrinol 5:347-358 (Pubitemid 44788152)
3. McClung M (2006) Bisphosphonates. Arq Bras Endocrinol Metabol 50:735-744 (Pubitemid 44786009)
4. Epstein S (2006) Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther 28:151-173
5. Marshall JK (2002) The gastrointestinal tolerability and safety of oral bisphosphonates. Exp Opin Drug Safety 1:71-78
6. Reginster JY, Felsenberg D, Cooper C, Stakkestad JA, Miller PD, Kendler DL, Adami S, McClung MR, Bolognese MA, Civitelli R, Dumont E, Bonvoisin B, Recker RR, Delmas PD (2006) A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Osteoporos Int 17:159-166 (Pubitemid 43053578)
7. Reginster JY (2006) Adherence and persistence: impact on outcomes and health care resources. Bone 38:18-21
8. Shane E, Goldring S, Christakos S, Drezner M, Eisman J, Silverman S, Pendrys D (2006) Osteonecrosis of the jaw: more research needed. J Bone Miner Res 21:1503-1505 (Pubitemid 44484594)
9. Boyce BF, Xing L, Yao Z, Shakespeare WC, Wang Y, Metcalf CA 3rd, Sundaramoorthi R, Dalgarno DC, Iuliucci JD, Sawyer TK (2006) Future anti-catabolic therapeutic targets in bone disease. Ann NY Acad Sci 1068:447-457 (Pubitemid 43824173)
10. Takahashi N, Udagawa M, Takami M, Suda T (2002) Cells of bone: osteoclast generation. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles of bone biology, 2nd edn. Academic, San Diego, pp 109-126
11. Väänänen K, Zhao H (2002) Osteoclast function: biology and mechanism. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles of bone biology, 2nd edn. Academic, San Diego, pp 127-139
12. Yasuda Y, Kaleta J, Bromme D (2005) The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev 57:973-993 (Pubitemid 40703885)
13. Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, Lee-Rykaczewski E, Coleman L, Rieman D, Barthlow R, Hastings G, Gowen M (1996) Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 271:12511-12516 (Pubitemid 26160923)
14. Gowen M, Lazner F, Dodds R, Kapadia R, Feild J, Tavaria M, Bertoncello I, Drake F, Zavarselk S, Tellis I, Hertzog P, Debouck C, Kola I (1999) Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 14:1654-1663 (Pubitemid 29455813)
15. Saftig P, Hunziker E,Wehmeyer O, Jones S, Boyde A, Rommerskirch W, Moritz JD, Schu P, von Figura K (1998) Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 95:13453-13458 (Pubitemid 28522993)
16. Marquis RW, Ru Y, Yamashita DS, Oh HJ, Yen J, Thompson SK, Carr TJ, Levy MA, Tomaszek TA, Ijames CF, Smith WW, Zhao B, Janson CA, Abdel-Meguid SS, D'Alessio KJ, McQueney MS, Veber DF (1999) Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K. Bioorg Med Chem 7:581-588 (Pubitemid 29150301)
17. Votta BJ, Levy MA, Badger A, Bradbeer J, Dodds RA, James IE, Thompson S, Bossard MJ, Carr T, Connor JR, Tomaszek TA, Szewczuk L, Drake FH, Veber DF, Gowen M (1997) Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J Bone Miner Res 12:1396-1406 (Pubitemid 27375382)
18. Stroup GB, Lark MW, Veber DF, Bhattacharyya A, Blake S, Dare LC, Erhard KF, Hoffman SJ, James IE, Marquis RW, Ru Y, Vasko-Moser JA, Smith BR, Tomaszek T, Gowen M (2001) Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res 16:1739-1746 (Pubitemid 32911477)
19. Kumar S, Dare L, Vasko-Moser JA, James IE, Blake SM, Rickard DJ, Hwang SM, Tomaszek T, Yamashita DS, Marquis RW, Oh H, Jeong JU, Veber DF, Gowen M, Lark MW, Stroup G (2007) A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 40:122-131 (Pubitemid 44839339)
20. Stroup GB, Kumar S, Jerome CP (2009) Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys. Calcif Tissue Int 85(4):344-355
21. Missbach M, Altmann E, Betschart C, Buhl T, Gamse R, Gasser JA, Green JR, Ishihara H, Jerome C, Kometani M, Susa M, Teno N, Toriyama K, Lattmann R (2005) AAE581, a potent and highly specific cathepsin K inhibitor, prevents bone resorption after oral treatment in rat and monkey. J Bone Miner Res 20(Suppl 1):S251
22. Jerome CP (1998) Primate models of osteoporosis. Lab Anim Sci 48:618-622 (Pubitemid 29075066)
23. Bayne K (1996) Revised guide for the care and use of laboratory animals available. Am Physiol Society Physiologist 39(199):208-211
24. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
25. Jerome CP, Power RA, Obasanjo IO, Register TC, Guidry M, Carlson CS, Weaver DS (1997) The androgenic anabolic steroid nandrolone decanoate prevents osteopenia and inhibits bone turnover in ovariectomized cynomolgus monkeys. Bone 20:355-364 (Pubitemid 27196659)
26. Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R (2001) Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 28:150-159 (Pubitemid 32140971)
27. Cusik T, Pennypacker B, Scott K, Duong L, Kimmel D (2009) Effects of odanacatib on bone mass, turnover and strength in the femoral neck of estrogen deficient adult rhesus monkeys. J Bone Miner Res 24(Suppl 1). Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid= 3c062e5c-74c9-4be1-b2c9-2935ae73f57e. Accessed June 1, 2010
28. Pennypacker B, Wesolowski G, Heo J, Duong L (2009) Effects of odanacatib on central femur cortical bone in estrogen deficient adult rhesus monkeys. J Bone Miner Res 24(Suppl 1). Available at http://www.asbmr.org/Meetings/ AnnualMeeting/AbstractDetail. aspx?aid=a11932a7-b4c2-4d38-9a9d-4ec165bb13f2. Accessed June 1, 2010
29. Xiang A, Kanematsu M, Kumar S, Yamashita D, Kaise T, Kikkawa H, Asano S, Kinoshita M (2010) Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone resorption and cortical bone formation in ovariectomized mice. Bone 40(5):1231-1237 (Pubitemid 46550989)
30. Lees CJ, Register TC, Turner CH, Wang T, Stancill M, Jerome CP (2002) Effects of raloxifene on bone density, biomarkers, and histomorphometric and biomechanical measures in ovariectomized cynomolgus monkeys. Menopause 9:320-328 (Pubitemid 36701891)
31. Feher A, Koivunemi A, Koivunemi M, Fuchs RK, Burr DB, Phipps RJ, Reinwald S, Allen MR (2010) Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading. Bone 46(1):203-207
32. Bare S, Recker S, Recker R, Kimmel D (2005) Influence of alendronate on periosteal and endocortical bone formation in the ilium of osteoporotic women. J Bone Miner Res 20(Suppl 1):SA414, Available at http://www.abstractsonline.com/ viewer/viewAbstractPrintFriendly.asp?CKey={320D85D2-5D21-4529-A15C-8B342938C99F} &SKey={BEF5BC3E-1AC0-489BA7FB-6F4FC82D96B1}&MKey={70A6304C-A41B- 49FCA4DF-C147A5E943F0}&AKey={D0C01D4F-E23B-45E2-ACD4-0AF8AC866B8B}. Accessed June 10, 2010
33. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15(4):613-620 (Pubitemid 30174014)
34. Itabashi A, Kurata N, Sugita Y, Kawai Y (2006) Balicatib, a novel cathepsin K-inhibitor, increases serum intact PTH beyond diurnal patterns following 14-daily administration in Japanese postmenopausal women. J Bone Miner Res 21(suppl 1):S24
35. Fuller K, Lawrence KM, Ross JL, Grabowska UB, Shiroo M, Samuelsson B, Chambers TJ (2008) Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone 42(1):200-211 (Pubitemid 350302017)